Skip to main content
Top
Published in: Abdominal Radiology 4/2008

01-07-2008

Radiofrequency ablation of problematically located hepatocellular carcinoma: tailored approach

Authors: Min-Hua Chen, Wei Yang, Kun Yan, Yi-Bin Hou, Ying Dai, Wen Gao, Hui Zhang, Wei Wu

Published in: Abdominal Radiology | Issue 4/2008

Login to get access

Abstract

Background

The challenge for radiofrequency ablation (RFA) of hepatocellular carcinomas (HCC) in problematic locations is that the outcome is limited due to insufficient ablation or injury of nearby structures. This study aimed to evaluate effective strategy and treatment results of RFA in these cases.

Methods

Ultrasound guided percutaneous RFA was performed in 326 HCC patients. Among them, 249 tumors in 215 patients located at liver periphery, including 54 adjacent to GI tract, 110 close to the diaphragm, 49 close to the gallbladder, and 36 tumors close to liver surface. The sizes of the tumors ranged 1.2–7.0 cm (average 3.7 ± 1.3 cm). Individualized treatment strategy was established for tumors in various locations, including “artificial ascites”, “lift-expand” electrode placement, “draw-expand” electrode placement, “Supplementary ablation”, and “accumulative multiple ablations” techniques. Treatment outcome was compared with another 64 central-located tumors (control group) in the same patients. One-month post-RFA contrast CT was used to evaluate early necrosis rate of the treated tumors.

Results

Early tumor necrosis were obtained in 91.6% (228/249) of the problematically located HCC, including 90.7% (49/54) of the tumors adjacent to GI tract, 90.9% (100/110) near the diaphragm, 91.8% (45/49) by the gallbladder, and 94.4% (34/36) close to liver surface. The necrosis rate of control group was 98.4% (63/64), which was higher than the tumors close to diaphragm (P = 0.049). Local tumor recurrence was 8.4% (21/249), comparing with 3.1% (2/64) of the control group (P > 0.05). The 1-, 2- and 3-year survival rate of this group were 81.6%, 63.8%, and 53.6%, respectively. Major complications occurred in 3.2% (11/343) of the treatment sessions, including hemorrhage in two, nearby structure injury in five, and needle tract seeding in four patients.

Conclusions

Individualized treatment strategy for problematically located HCC is helpful in improving RFA outcome and expanding the application range of the therapy.
Literature
1.
go back to reference Curley SA, Izzo F, Delrio P, et al. (1999) Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. Ann Surg 230:1–8PubMedCrossRef Curley SA, Izzo F, Delrio P, et al. (1999) Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. Ann Surg 230:1–8PubMedCrossRef
2.
go back to reference Gazelle GS, Goldberg SN, Solbiati L, et al. (2000) Tumor ablation with radio-frequency energy. Radiology 217:633–646PubMed Gazelle GS, Goldberg SN, Solbiati L, et al. (2000) Tumor ablation with radio-frequency energy. Radiology 217:633–646PubMed
3.
go back to reference Livraghi T, Goldberg SN, Lazzaroni S, et al. (1998) Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 210: 655–661 Livraghi T, Goldberg SN, Lazzaroni S, et al. (1998) Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 210: 655–661
4.
go back to reference Livraghi T, Goldberg SN, Lazzaroni S, et al. (2000) Hepatocellular carcinoma: radiofrequency ablation of medium and large lesions. Radiology 214:761–768PubMed Livraghi T, Goldberg SN, Lazzaroni S, et al. (2000) Hepatocellular carcinoma: radiofrequency ablation of medium and large lesions. Radiology 214:761–768PubMed
5.
go back to reference Chen MH, Yang W, Yan K, et al. (2004) Large liver tumors: protocol for radiofrequency ablation and its clinical application in 110 patients-mathematic model, overlapping mode, and electrode placement process. Radiology 232:260–271PubMedCrossRef Chen MH, Yang W, Yan K, et al. (2004) Large liver tumors: protocol for radiofrequency ablation and its clinical application in 110 patients-mathematic model, overlapping mode, and electrode placement process. Radiology 232:260–271PubMedCrossRef
6.
go back to reference Yamamoto J, Kosuge T, Takayama T, et al. (1996) Recurrence of hepatocellular carcinoma after surgery. Br J Surg 83:1219–1222PubMedCrossRef Yamamoto J, Kosuge T, Takayama T, et al. (1996) Recurrence of hepatocellular carcinoma after surgery. Br J Surg 83:1219–1222PubMedCrossRef
7.
go back to reference Poon RT, Fan ST, Lo CM, et al. (1999) Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg 229:216–222PubMedCrossRef Poon RT, Fan ST, Lo CM, et al. (1999) Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg 229:216–222PubMedCrossRef
8.
go back to reference Yang W, Chen MH, Yan K, et al. (2002) Study of calculating method for ablation area and program for electrode placement by ultrasound-guided radiofrequency ablation of large liver tumors. Chin J Ultrasonogr 11:244–247 Yang W, Chen MH, Yan K, et al. (2002) Study of calculating method for ablation area and program for electrode placement by ultrasound-guided radiofrequency ablation of large liver tumors. Chin J Ultrasonogr 11:244–247
9.
go back to reference Chen MH, Yang W, Yan K, et al. (2006) Treatment strategy to optimize radiofrequency ablation for liver malignancies. JVIR 17:671–683PubMed Chen MH, Yang W, Yan K, et al. (2006) Treatment strategy to optimize radiofrequency ablation for liver malignancies. JVIR 17:671–683PubMed
10.
go back to reference Chopra S, Dodd III GD, Chanin MP, et al. (2003) Radiofrequency ablation of hepatic tumors adjacent to the gallbladder: feasibility and safety. Am J Roentgenol 180:697–701 Chopra S, Dodd III GD, Chanin MP, et al. (2003) Radiofrequency ablation of hepatic tumors adjacent to the gallbladder: feasibility and safety. Am J Roentgenol 180:697–701
11.
go back to reference Choi D, Lim HK, Kim MJ, et al. (2004) Therapeutic efficacy and safety of percutaneous radiofrequency ablation of hepatocellular carcinoma abutting the gastrointestinal tract. Am J Roentgenol 183:1417–1424 Choi D, Lim HK, Kim MJ, et al. (2004) Therapeutic efficacy and safety of percutaneous radiofrequency ablation of hepatocellular carcinoma abutting the gastrointestinal tract. Am J Roentgenol 183:1417–1424
12.
go back to reference Teratani T, Yoshida H, Shiina S, et al. (2006) Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations. Hepatology. 43:1101–1108PubMedCrossRef Teratani T, Yoshida H, Shiina S, et al. (2006) Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations. Hepatology. 43:1101–1108PubMedCrossRef
13.
go back to reference Zhao WH, Feng YZ, Ma ZM, et al. (2001) Prognostic factors of patients with hepatoculluar carcinoma after hepatectomy. Chin J Gen Surg 16:472–474 Zhao WH, Feng YZ, Ma ZM, et al. (2001) Prognostic factors of patients with hepatoculluar carcinoma after hepatectomy. Chin J Gen Surg 16:472–474
14.
go back to reference Poon RT, Fan ST, Lo CM, Liu CL, Wong J (2002) Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implication for a strategy of salvage transplantation. Ann Surg 235:373–382PubMedCrossRef Poon RT, Fan ST, Lo CM, Liu CL, Wong J (2002) Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implication for a strategy of salvage transplantation. Ann Surg 235:373–382PubMedCrossRef
15.
go back to reference Nagasue N, Yukayu H (1989) Liver resection for hepatocellular carcinoma: results from 150 consecutive patients. Cancer Chemother Pharmacol 23:S78–S82PubMedCrossRef Nagasue N, Yukayu H (1989) Liver resection for hepatocellular carcinoma: results from 150 consecutive patients. Cancer Chemother Pharmacol 23:S78–S82PubMedCrossRef
16.
go back to reference Livraghi T, Solbiati L, Meloni MF, et al. (2003) Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology 226:441–451PubMedCrossRef Livraghi T, Solbiati L, Meloni MF, et al. (2003) Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology 226:441–451PubMedCrossRef
17.
go back to reference Kato T, Reddy KR (2001) Radiofrequency—ablation for hepatocellular carcinoma: help or hazard? Hepatology 33:1336–1337PubMedCrossRef Kato T, Reddy KR (2001) Radiofrequency—ablation for hepatocellular carcinoma: help or hazard? Hepatology 33:1336–1337PubMedCrossRef
18.
go back to reference Llovet JM,Vilana R, Bru C, et al. (2001) Increased risk of tumor seeding after Percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology 33:1124–1129PubMedCrossRef Llovet JM,Vilana R, Bru C, et al. (2001) Increased risk of tumor seeding after Percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology 33:1124–1129PubMedCrossRef
19.
go back to reference Rhim H, Yoon KH, Lee JM, et al. (2003) Major complications after radio-frequency thermal ablation of hepatic tumors: spectrum of imaging findings. Radiographics 23: 123–136PubMedCrossRef Rhim H, Yoon KH, Lee JM, et al. (2003) Major complications after radio-frequency thermal ablation of hepatic tumors: spectrum of imaging findings. Radiographics 23: 123–136PubMedCrossRef
Metadata
Title
Radiofrequency ablation of problematically located hepatocellular carcinoma: tailored approach
Authors
Min-Hua Chen
Wei Yang
Kun Yan
Yi-Bin Hou
Ying Dai
Wen Gao
Hui Zhang
Wei Wu
Publication date
01-07-2008
Publisher
Springer-Verlag
Published in
Abdominal Radiology / Issue 4/2008
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-007-9283-4

Other articles of this Issue 4/2008

Abdominal Radiology 4/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine